Apertura Gene Therapy

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

It took four weeks, but the second quarter of 2022 finally has its first two biopharmaceutical initial public offerings in the US, launched by HilleVax, Inc. and Belite Bio late on 28 April. The o